1. Long-term durability of Edwards bioprosthetic aortic valves
Evidence from large, long-term follow-up studies

2. Excellent long-term durability (1/2)
Expected valve durability:*1–3
17.6 years for patients aged ≤60 years at implantation
19 years for patients aged 50–65 years at implantation
22.1 years for patients aged 60–70 years at implantation
Expected valve durability* according to age at implantation1–3
*Defined as median survival time without echocardiographically-assessed structural valve deterioration
Bourguignon T et al. Ann Thorac Surg. 2015; 99: 831–7
Bourguignon T et al. Eur J Cardiothorac Surg. 2015; 49: 1462–68
Bourguignon T et al. Ann Thorac Surg. 2015; 100: 853–9

3. Excellent long-term durability (2/2)
Expected valve durability exceeded life expectancy post-AVR for all age groups examined1
Comparison of expected valve durability, life expectancy after aortic valve replacement and relative life expectancy of the general population in France1
AVR: aortic valve replacement
PERIMOUNT is a trademark or service mark of Edwards Lifesciences Corporation.
© 2017 Edwards Lifesciences Corporation. All right reserved.
Bourguignon T et al. Ann Thorac Surg. 2015; 99: 831–7

4. Low risk of reoperation due to SVD
Risk of reoperation due to SVD in a very long-term follow-up of 12,569 patients post-AVR was 5.4% at 20 years1
Younger age at implantation was associated with an increased risk of reoperation due to SVD1,2
Cumulative risk of reoperation due to SVD for different age groups2
AVR: aortic valve replacement; SVD: structural valve deterioration
Johnston DR et al. Ann Thorac Surg. 2015; 99: 1239–47
Bourguignon T et al. Ann Thorac Surg. 2015; 99: 831–7

5. Freedom from reoperation due to SVD
In long-term follow up studies in various post-AVR populations, long-term freedom from reoperation at 15 years ranged from 78.3% to 87.5%1–3
Again, younger age was a risk factor for reoperation due to SVD2–5
Freedom from reoperation due to SVD for different age groups at 5, 10 and 15 years post-implantation1
AVR: aortic valve replacement; SVD: structural valve deterioration
Bourguignon T et al. Ann Thorac Surg. 2015; 99: 831–7
Bourguignon T et al. Ann Thorac Surg. 2015; 100: 853–9.
McClure RS et al. Ann Thorac Surg. 2010; 89: 1410–16
Bourguignon T et al. Eur J Cardiothorac Surg. 2015; 49: 1462–8
Minakata K et al. Circ J. 2014; 78: 882–9

6. Key learnings
Several recent studies have examined the long-term durability of Edwards bioprosthetic aortic valves1–9
Expected valve durability (defined as median survival time without echocardiographically-assessed SVD), is 17.6 years for patients aged ≤60 years, 19 years for patients aged 50–65 years and 22.1 years patients aged 60–70 years1-3
20-year probability of explant due to SVD across all age groups is 5.4%4
Younger age at implantation is associated with a higher risk of SVD, but durability is good even in these younger patients1,4,5,8,9
SVD: structural valve deterioration
Minakata K et al. Circ J. 2014; 78: 882–9
Bourguignon T et al. Ann Thorac Surg. 2015; 99: 831–7
Minakata K et al. J Card Surg. 2015; 30: 405–13
Bourguignon T et al. Ann Thorac Surg. 2015; 100: 853–9
Forcillo J et al. Ann Thorac Surg. 2014; 97: 1526–32
Bourguignon T et al. Eur J Cardiothorac Surg. 2015; 49: 1462–8
Forcillo J et al. Ann Thorac Surg. 2013; 96: 486–93
Johnston DR et al. Ann Thorac Surg. 2015; 99: 1239–47
McClure RS et al. Ann Thorac Surg. 2010; 89: 1410–16